Cardiovascular diseases are life-threatening illnesses with high morbidity and mortality. Suppressed vagal(parasympathetic) activity and increased sympathetic activity are involved in these diseases. Currently, pharma...Cardiovascular diseases are life-threatening illnesses with high morbidity and mortality. Suppressed vagal(parasympathetic) activity and increased sympathetic activity are involved in these diseases. Currently, pharmacological interventions primarily aim to inhibit overexcitation of sympathetic nerves, while vagal modulation has been largely neglected. Many studies have demonstrated that increased vagal activity reduces cardiovascular risk factors in both animal models and human patients.Therefore, the improvement of vagal activity may be an alternate approach for the treatment of cardiovascular diseases. However, drugs used for vagus nerve activation in cardiovascular diseases are limited in the clinic. In this review, we provide an overview of the potential drug targets for modulating vagal nerve activation, including muscarinic, and b-adrenergic receptors. In addition,vagomimetic drugs(such as choline, acetylcholine, and pyridostigmine) and the mechanism underlying their cardiovascular protective effects are also discussed.展开更多
基金supported by grants from the National Natural Science Foundation of China(81770293 and 81473203)
文摘Cardiovascular diseases are life-threatening illnesses with high morbidity and mortality. Suppressed vagal(parasympathetic) activity and increased sympathetic activity are involved in these diseases. Currently, pharmacological interventions primarily aim to inhibit overexcitation of sympathetic nerves, while vagal modulation has been largely neglected. Many studies have demonstrated that increased vagal activity reduces cardiovascular risk factors in both animal models and human patients.Therefore, the improvement of vagal activity may be an alternate approach for the treatment of cardiovascular diseases. However, drugs used for vagus nerve activation in cardiovascular diseases are limited in the clinic. In this review, we provide an overview of the potential drug targets for modulating vagal nerve activation, including muscarinic, and b-adrenergic receptors. In addition,vagomimetic drugs(such as choline, acetylcholine, and pyridostigmine) and the mechanism underlying their cardiovascular protective effects are also discussed.
